2 assets in Ovarian Endometrial Cancer

Therapeutic assets addressing Ovarian Endometrial Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Ovarian Endometrial Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Ovarian Endometrial Cancer	National Cancer Institute (NCI)	P2	CCC (53)